Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Recurrent Digestive System Carcinoma

Known as: Recurrent Gastrointestinal System Cancer, Recurrent Gastrointestinal System Carcinoma 
The reemergence of carcinoma in any part of the digestive system after a period of remission.
National Institutes of Health

Related topics

Related topics

7 relations
Epithelial CellsEpitheliumGastrointestinal systemMalignant Epithelial Cell
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 2
2016
2016
A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer
PurposesTo determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined oxaliplatin, irinotecan… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2014
2014
[Value of the palliative prognostic index, controlling nutritional status, and prognostic nutritional index for objective evaluation during transition from chemotherapy to palliative care in cases of…
OBJECTIVE We investigated whether objective evaluation by using the palliative prognostic index(PPI), controlling nutritional… Expand
2014
2014
671PDOSE FINDING STUDY OF OXALIPLATIN, IRINOTECAN, AND S-1 FOR PATIENTS WITH METASTATIC OR RECURRENT GASTROINTESTINAL CANCER.
  • B. Han, H. Kim, +11 authors D. Zang
  • Annals of oncology : official journal of the…
  • 2014
    • Corpus ID: 1346686
ABSTRACT Aim: To determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined oxaliplatin… Expand
2013
2013
Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer
Background:The clinical significance of circulating tumour cell (CTC) detection in gastrointestinal (GI) cancer remains… Expand
  • figure 1
  • table 1
  • table 2
2010
2010
[Oral rehydration therapy with OS-1 for advanced and recurrent gastrointestinal cancer patients].
The aim of this study was to introduce an oral rehydration therapy with OS-1 for advanced and recurrent gastrointestinal cancer… Expand
2004
2004
A phase I study of immunotherapy with tumor cell-dendritic cell fusion vaccine in patients with advanced or recurrent gastrointestinal cancer
2615 Background: Immunotherapy with tumor cell-dendritic cell fusion vaccine has been shown to induce the immune response against… Expand
2004
2004
A phase I study of immunotherapy with tumor cell-dendritic cell fusion vaccine in patients with advanced or recurrent gastrointestinal cancer.
2615 Background: Immunotherapy with tumor cell-dendritic cell fusion vaccine has been shown to induce the immune response against… Expand
1990
1990
[Early phase II study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90…
Early phase II study in patients with advanced and recurrent gastrointestinal cancer was conducted from August 1986 through… Expand
Highly Cited
1985
Highly Cited
1985
Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer.
In our study of patients with resected primary gastrointestinal cancer, slope analysis of the post-operatively increasing… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE